TW202317192A - 用於阿茲海默氏症治療的生物標記物 - Google Patents

用於阿茲海默氏症治療的生物標記物 Download PDF

Info

Publication number
TW202317192A
TW202317192A TW111125802A TW111125802A TW202317192A TW 202317192 A TW202317192 A TW 202317192A TW 111125802 A TW111125802 A TW 111125802A TW 111125802 A TW111125802 A TW 111125802A TW 202317192 A TW202317192 A TW 202317192A
Authority
TW
Taiwan
Prior art keywords
subject
months
antibody
ratio
therapeutically effective
Prior art date
Application number
TW111125802A
Other languages
English (en)
Chinese (zh)
Inventor
米雪兒 愛里沙瑞
查德 史旺森
琳恩 卡莫
小山彰比古
珍 卡普洛
大衛 維貝爾
薩布哈 達哈達
帕拉宜 薩迪夫
拉里薩 瑞德曼
早戶誠一
道夫 金清
伊瑄妮 蘭德瑞
羅伯特 戈登
Original Assignee
日商衛材R&D企管股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商衛材R&D企管股份有限公司 filed Critical 日商衛材R&D企管股份有限公司
Publication of TW202317192A publication Critical patent/TW202317192A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
TW111125802A 2021-07-09 2022-07-08 用於阿茲海默氏症治療的生物標記物 TW202317192A (zh)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US202163220434P 2021-07-09 2021-07-09
US63/220,434 2021-07-09
US202163203444P 2021-07-22 2021-07-22
US63/203,444 2021-07-22
US202163263255P 2021-10-29 2021-10-29
US63/263,255 2021-10-29
US202163263928P 2021-11-11 2021-11-11
US63/263,928 2021-11-11
US202163264551P 2021-11-24 2021-11-24
US63/264,551 2021-11-24
US202263306028P 2022-02-02 2022-02-02
US63/306,028 2022-02-02
US202263269372P 2022-03-15 2022-03-15
US63/269,372 2022-03-15
US202263364618P 2022-05-12 2022-05-12
US63/364,618 2022-05-12

Publications (1)

Publication Number Publication Date
TW202317192A true TW202317192A (zh) 2023-05-01

Family

ID=83232761

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111125802A TW202317192A (zh) 2021-07-09 2022-07-08 用於阿茲海默氏症治療的生物標記物

Country Status (11)

Country Link
US (1) US20250163135A1 (cg-RX-API-DMAC7.html)
EP (1) EP4367516A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024525559A (cg-RX-API-DMAC7.html)
KR (1) KR20240033017A (cg-RX-API-DMAC7.html)
AU (1) AU2022307687A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225302A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000063A1 (cg-RX-API-DMAC7.html)
IL (1) IL309468A (cg-RX-API-DMAC7.html)
MX (1) MX2023015183A (cg-RX-API-DMAC7.html)
TW (1) TW202317192A (cg-RX-API-DMAC7.html)
WO (1) WO2023283650A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120076808A (zh) 2022-09-23 2025-05-30 卫材R&D管理有限公司 减少与神经退行性疾病相关的神经退行性变的方法
WO2025019457A1 (en) * 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025260029A1 (en) 2024-06-14 2025-12-18 Eisai R&D Management Co., Ltd. Method for quantifying amyloid beta protofibril
CN118777453B (zh) * 2024-06-25 2025-04-08 上海交通大学医学院附属瑞金医院 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
PT4121007T (pt) 2020-03-20 2025-09-25 Eisai R&D Man Co Ltd Formulações de anticorpo de protofibrila de péptido anti-beta amiloide de concentração alta e métodos de uso das mesmas
CA3172451A1 (en) * 2020-04-03 2021-10-07 Robert Paul Methods of use of anti-trem2 antibodies
TWI843040B (zh) * 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途

Also Published As

Publication number Publication date
WO2023283650A1 (en) 2023-01-12
IL309468A (en) 2024-02-01
CL2024000063A1 (es) 2024-08-02
JP2024525559A (ja) 2024-07-12
CA3225302A1 (en) 2023-01-12
MX2023015183A (es) 2024-03-14
US20250163135A1 (en) 2025-05-22
EP4367516A1 (en) 2024-05-15
KR20240033017A (ko) 2024-03-12
AU2022307687A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
JP7676556B2 (ja) 抗N3pGluアミロイドベータ抗体及びその使用
US20250163135A1 (en) Biomarkers for alzheimer's disease treatment
TW202339794A (zh) 使用p—tau181水平之治療方法
JP7792428B2 (ja) 抗アミロイドベータ抗体及びその使用
WO2017211827A1 (en) Methods for treating alzheimer's disease
TW202430554A (zh) 使用tau PET水平之治療方法
JP2024547001A (ja) 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法
TW202328178A (zh) 抗Aβ初原纖維抗體的皮下配製物及其使用方法
CN117940773A (zh) 用于阿尔茨海默病治疗的生物标记物
CN118786141A (zh) 使用p-tau181水平的治疗方法
WO2026075947A1 (en) Dosing regimens for early alzheimer's disease
KR20260022396A (ko) 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
EA052116B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и варианты их применения
KR20260038283A (ko) 항미생물 펩티드